On statins: a race-related update

It is relatively common knowledge — although never actually proven in a large, randomized, placebo-controlled trial — that statins like rosuvastatin (Crestor) and atorvastatin (Lipitor) may be helpful in the management of prostate cancer. … READ MORE …

How 48 doctors think about active surveillance

Many patients, prostate cancer advocates, and prostate cancer educators may be interested in a recent article exploring how physicians who manage prostate cancer regularly think about active surveillance (AS) and how to discuss this with their patients. … READ MORE …

Improving prognostic guidance for men with advanced and progressive forms of prostate cancer

A recent report on Renal & Urology News discusses long-term follow-up data from a cohort of > 2,600 prostate cancer patients who were followed from diagnosis for up to 10 years until their deaths. … READ MORE …

Some recent videos on the UroToday web site

One has to sign up to become a member of the UroToday web site, but there is no cost involved, and an attractive feature for prostate cancer patients is the regular, relatively brief, video-recorded interviews with experts on recent, specific issues. … READ MORE …

Active surveillance in Oz: a situation report

An interesting article published a couple of week’s ago in the Medical Journal of Australia reports on “real world issues” related to the implementation of active surveillance (AS) in Oz. … READ MORE …

Is it or ain’t it “really” cancer?

In a new article in the Journal of Urology, researchers at Johns Hopkins Medical Center in Baltimore have again expressed their opinion that it would be inappropriate to rename low-risk Gleason 6 disease as something other than “cancer”. … READ MORE …

VTP in the focal therapy of low-risk, localized prostate cancer

We have previously reported data from the 2-year follow-up of the patients participating in the PCM301 trial of vascular targeted phototherapy (VTP) — a form of prostate hemiablation — compared to active surveillance in the treatment of low-risk, localized prostate cancer. New data at 4 years of follow-up have now been published in the Journal of Urology. … READ MORE …